Health Canada has approved the first generic version of semaglutide, the active ingredient in popular brand-name drugs like Ozempic. This makes Canada the first G7 nation to authorize a generic equivalent.
Manufactured by India-based Dr. Reddy’s Laboratories, the injectable medication, sold as "Obeda" in India, is approved for once-weekly treatment of Type 2 diabetes in adults. Health Canada confirmed eight other generic semaglutide submissions are under review.
Experts emphasize that approved generic drugs undergo a rigorous process to ensure chemical similarity to the original, promising comparable therapeutic effects.
While the average monthly cost for Ozempic injections in Canada can range from $200 to $450, preliminary estimates suggest generic versions could be significantly cheaper. Pricing structures indicate the first generic typically costs 75-85% less than the brand-name drug, with prices dropping further as more generics enter the market.
Some experts project costs as low as $40 to $80 per month for generic semaglutide, representing a substantial decrease.
However, provincial coverage for generic semaglutide remains uncertain, as reimbursement decisions vary by province. Experts note that integrating these lower-cost generics into public drug plans could yield significant savings for the healthcare system by reducing costs associated with obesity and related chronic diseases.
Patients considering the medication are advised that benefits are contingent on continuous use, as stopping treatment can reverse improvements in weight and glucose control.